摘要
目的探讨联用普伐他汀和非诺贝特治疗混合型高血脂症的临床疗效。方法按照随机数字法将211例混合型高血脂症患者随机分为联合组、普伐他汀组和非诺贝特组,其中联合组采用低剂量的普伐他汀与非诺贝特联合治疗,普伐他汀组和非诺贝特组分别采用普伐他汀和非诺贝特单独治疗,比较三组的临床血脂指标、疗效和不良反应。结果联合组的总有效率明显高于普伐他汀组和非诺贝特组(P<0.05)。三组的不良反应无明显差异(P>0.05)。结论联用普伐他汀和非诺贝特治疗混合型高血脂症具有良好的临床疗效,且不良反应少,值得临床推广使用。
Objective To investigate the clinical effect of pravastatin and fenofibrate in treatment of mixed hyperlipidemia. Methods All of 211 cases of mixed hyperlipidemia patients were randomly divided into combined group, pravastatin group and fenofibrate group, in which low-dose combination group fenofibrate combination therapy with pravastatin, pravastatin group and fenofibrate group were used to separate treatment of pravastatin and fenofibrate. Clinical lipid levels, efficacy and adverse reactions compared in three groups. Results The total effective rate of combined group was significantly higher than pravastatin group and fenofibrate group （P 〈 0.05）. Three groups had no significant difference in adverse events （P 〉 0.05）. Conclusion Pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia has a good clinical efficacy, fewer adverse reactions. So it is worthy of clinical use.
出处
《中国现代医生》
2012年第6期39-40,共2页
China Modern Doctor
